Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin-assisted psychotherapy for major depressive disorder
ACTRN12625000799459Phase 2Not yet recruiting
- Sponsor
- Monash University
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of psilocybin in major depressive disorder (MDD) (3 arms), sponsored by Monash University. Primary endpoint: Primary efficacy of FIFO-PAT versus TAU for major depressive disorder. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ACTRN12625000799459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000799459.